|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.
|
12801613 |
2003 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the association between PAI-1-844G/A and 4G/5G polymorphisms and changes in PAI-1 and tissue plasminogen activator (tPA) levels in MI in a Tunisian population.
|
19929406 |
2010 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with myocardial infarction and stroke, especially in patients with diabetes.
|
15956119 |
2005 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults.
|
17126309 |
2007 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Multivariable logistic regression analyses and stepwise forward selection procedures revealed that seven different polymorphisms were significantly (P<0.005) associated with MI in individuals with low or high serum concentrations of HDL- or LDL-cholesterol or of TG: the 190T --> C (Trp64Arg) polymorphism of ADRB3 in individuals with low HDL-cholesterol; the 1018C --> T (Thr145Met) polymorphism of GP1BA, the A --> G (Ile646Val) polymorphism of AKAP10, and the -55C --> T polymorphism of UCP3 in individuals with high HDL-cholesterol; the -603A --> G polymorphism of F3 and the -11377C --> G polymorphism of ADIPOQ in individuals with low LDL-cholesterol; the 1018C --> T polymorphism of GP1BA in individuals with low TG; and the 4G --> 5G polymorphism of PAI1 in individuals with high TG.
|
17786291 |
2007 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
PAI-1 4G/4G genotype was the only independent variable (OR 2.67, 95%CI 1.43-4.96, P = 0.002) associated with MI in this regression model.
|
17721742 |
2008 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Recent large Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for MI, but the prevalence of these genotypes among different racial groups in the U.S. needs to be determined.
|
15234427 |
2004 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
RGD |
Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction.
|
16053971 |
2005 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
|
9285181 |
1997 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
SERPINE1 haplotypes are mildly associated with plasma levels of PAI-1 and with the risk of MI in nonsmokers.
|
17656673 |
2007 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
PAI-1 4G/4G genotype was the only independent variable (OR 2.67, 95%CI 1.43-4.96, P = 0.002) associated with MI in this regression model.
|
17721742 |
2008 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Genetic control of PAI-1 expression has also been shown, involving a -675 4G/5G polymorphism, the 4G/4G genotype being associated with higher plasma PAI-1 levels; its proper influence on the development of myocardial infarction is still debated.
|
10980830 |
1999 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
|
10577569 |
1999 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
PAI-1 activity levels were also determined in the men who suffered a premature myocardial infarction 4 months after their discharge.
|
8883280 |
1996 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Recent large Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for MI, but the prevalence of these genotypes among different racial groups in the U.S. needs to be determined.
|
15234427 |
2004 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We assessed the 4G/5G polymorphism of the PAI-I gene in 500 subjects including 148 normal controls, 23 subjects with normal coronary arteries, 28 subjects with a paradoxical acetylcholine response, 97 subjects with angina pectoris (AP) and 204 subjects with myocardial infarction (MI).
|
9544737 |
1998 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that PAI-1 promoter polymorphism influences the development of myocardial infarction through its effect on thrombus formation in patients with preexisting coronary atheroma.
|
9012634 |
1997 |
|
SERPINE1
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The PAI-1 promoter 4G/5G polymorphism, furthermore, regulates free plasma PAI-1 levels in patients with myocardial infarction.
|
12065877 |
2002 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The PAI-1 4G/5G genotype was not associated with risk of myocardial infarction or other cardiovascular mortality.
|
10618306 |
2000 |
|
SERPINE1
|
0.300 |
Biomarker
|
disease |
BEFREE |
Myocardial infarction occurs with a similar 24 h pattern in the 4G/5G versions of plasminogen activator inhibitor-1.
|
19444746 |
2009 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The Mendelian randomization meta-analysis confirmed previous knowledge that the PAI-1 4G allele slightly increases the risk for MI.
|
24695040 |
2014 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The 4G allele is associated with higher PAI-1 levels, but this study does not support an association of the PAI gene polymorphisms with the risk of either myocardial infarction or stroke.
|
17161063 |
2006 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In a multiple logistic regression analysis, age (OR 1.02 [95%-CI: 1.00-1.05]), total cholesterol (OR 1.40 [95%-CI: 1.14-1.71]), C-reactive protein levels >0.33 mg/l (OR: 1.87 [95%-CI: 1.10-3.20]), plasminogen activator inhibitor-1 4G/4G (OR: 1.84 [95%-CI: 1.27-2.66]), and MTHFR TT genotype (OR 1.62 [95%-CI: 1.08-2.42]), were all associated with a family history of myocardial infarction.
|
10456448 |
1999 |
|
SERPINE1
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and tissue plasminogen activator (tPA, PLAT), such as PAI-1 (-675 4G/5G deletion/insertion) and tPA (Alu insertion/deletion [I/D]), are associated with strokes, myocardial infarctions, bacterial infections and septic shock severity, and trauma.
|
23570848 |
2013 |